Therapeutic Pipeline Tracker

Explore nonprofit patient-led drug development programs across all stages.

Making Patient-Led Therapeutic Development Visible and Investable

Across ultra-rare diseases, patient organizations are advancing real therapeutic development programs, from natural history studies to preclinical and clinical assets. Yet this work is often fragmented and invisible beyond individual diseases.

The Patient-Led Pipeline Tracker brings these efforts together in a single, living view to show that patient-led therapeutic development is not anecdotal. It is a growing, disciplined, and investable area of activity.

By aggregating programs across diseases and stages, the tracker:

  • Increases visibility for patient-led programs
  • Signals readiness to funders, investors, and partners
  • Reduces friction for collaboration and follow-on capital

For patient groups, the tracker offers visibility and connection.

For funders and investors, it provides a transparent view into an emerging pipeline of ultra-rare programs.

This is infrastructure for a new category of medicine, built by patients and designed to scale.

 

Disclaimer: All programs listed in the Buffalo Patient-Powered Pipeline Tracker are self-reported by the submitting organizations. Buffalo has not independently verified, validated, or conducted due diligence on the scientific, clinical, or commercial claims associated with these programs. Buffalo does not endorse individual programs. Content is provided to increase access, awareness and transparency.

Type of Therapy

Development Stage

Therapeutic Area

Search Programs

Search Programs

Therapeutic Modalities

Therapeutic Modalities

Therapeutic Area

Therapeutic Area

Development Stage

Development Stage

Sort Programs By:

Sort Programs By:
5p- Syndrome

Program Name:

ASO for 5p- Syndrome
Neurology
Nucleic Acid/RNA/ASO

Development Stage:

Preclinical Phase - Target Validation
5p- Syndrome

Program Name:

Repurposing Screen
Neurology
Small Molecule (novel)

Development Stage:

Preclinical Phase - Target Validation
Adenylosuccinate Synthase 1 (ADSS1) Myopathy

Program Name:

Subcutaneous ASA-001 (Adenylosuccinic Acid)
Neurology
Small Molecule (novel)

Development Stage:

Phase I Clinical Trial
Alternating Hemiplegia of Childhood

Program Name:

Prime editing for Alternating Hemiplegia of Childhood (Liu Lab)
Neurology
Gene Editing

Development Stage:

Preclinical Phase - Target Validation
CACNA1A-related disorders

Program Name:

CACNA1A Upregulating ASO
Neurology
Nucleic Acid/RNA/ASO

Development Stage:

Preclinical Phase - Preclinical Proof of Concept
CACNA1A-related disorders

Program Name:

CACNA1A Drug Repurposing
Neurology
Small Molecule (repurposed)

Development Stage:

Preclinical Phase - Target Validation
CASK gene disorder

Program Name:

Small molecule for CASK gene disorder
Neurology
Small Molecule (novel)

Development Stage:

Preclinical Phase - Target Validation